Chemours Company
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.47%.
Did CC Beat Earnings? Q3 2025 Results
Chemours posted a mixed third quarter for fiscal 2025, missing on earnings while landing essentially in line on the top line, as a powerful surge in refrigerant demand failed to fully offset deep weakness elsewhere in its portfolio. The specialty chemicals company reported adjusted EPS of $0.20, falling 17.22% short of the $0.24 consensus estimate, while revenue of $1.50 billion came in roughly flat year-over-year, down just 0.4%, and fractionally below expectations. The headline story was the stark divergence between segments: Thermal and Specialized Solutions delivered 20% net sales growth to $560.00 million, powered by Opteon refrigerant revenues surging 80% to $368.00 million as AIM Act-driven demand accelerated the stationary air conditioning transition, but those gains were undercut by a 68% collapse in Titanium Technologies' Adjusted EBITDA and a 63% drop in Advanced Performance Materials, the latter hit by a costly Washington Works facility outage. Looking ahead, management guided Q4 net sales 10-15% lower sequentially, with full-year 2025 Adjusted EBITDA targeted between $745.00 million and $770.00 million.
- Strong Opteon Refrigerant demand driven by U.S. AIM Act stationary AC transition
- 80% year-over-year growth in Opteon Refrigerant sales, now comprising 80% of total refrigerant revenues
- Resolved outage at APM Washington Works site that had depressed volumes and incurred ~$20M in costs
- Operational disruptions in TT business added ~$11M in costs
- Global TiO2 market weakness resulting in 8% price decline
- Lower capital expenditures of $41M vs $76M year-over-year
“Our consolidated results exceeded our expectations for the quarter, driven by continued strong demand for Opteon™ products, paired with a focus on enhancing operational excellence, driving stability in our operations to resolve disruptions, and ensure improved performance going forward.”
Chemours CEO, on the earnings call
Forward Guidance & Outlook
For Q4 2025, Chemours expects consolidated net sales to decrease 10-15% sequentially with Adjusted EBITDA of $130-$160 million. Corporate expenses are expected to be $40-$45 million. Capital expenditures are anticipated at approximately $50 million with Free Cash Flow Conversion of 50-70%. TSS expects a high-teens to low-twenties percent sequential net sales decrease with Adjusted EBITDA of $125-$140 million. TT expects a high single-digit to low-teens percent sequential net sales decrease with Adjusted EBITDA of $15-$20 million, including a $25 million cost impact from production volume adjustments. APM expects a low single-digit percent sequential net sales decrease with Adjusted EBITDA of $30-$40 million as Washington Works returns to normal operations. For full-year 2025, the company estimates net loss attributable to Chemours of $335-$318 million and Adjusted EBITDA of $745-$770 million.
CC YoY Financials
CC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.